Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jan 2024 According to Sanofi media release, based on data from this study the U.S. Food and Drug Administration (FDA) has updated the label for Dupixent (dupilumab).
18 Mar 2023 Results presented in the Regeneron Pharmaceuticals Media Release.
18 Mar 2023 Primary endpoint has been met. (Proportion of patients achieving an Investigator Global Assessment (IGA) (hand and foot) score of 0 or 1), according to a Regeneron Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com